AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.58
-0.16 (-2.79%)
Aug 28, 2026, 4:00 PM EDT - Market closed
AN2 Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 44.32 | 19.94 | 21.35 | 15.65 | 27.22 | 12.1 |
Short-Term Investments | 34.07 | 38.06 | 62.27 | 91.65 | 68.84 | 46.46 |
Cash & Short-Term Investments | 78.39 | 58 | 83.62 | 107.3 | 96.06 | 58.56 |
Cash Growth | 24.59% | -30.64% | -22.07% | 11.70% | 64.05% | 1338.70% |
Other Receivables | 0.3 | 0.9 | 0.3 | 1.4 | - | - |
Receivables | 0.3 | 0.9 | 0.3 | 1.4 | - | - |
Prepaid Expenses | 1.3 | 1.04 | 2.34 | 1.81 | 2.51 | 1.55 |
Other Current Assets | - | - | - | - | 0.05 | - |
Total Current Assets | 79.99 | 59.94 | 86.26 | 110.51 | 98.62 | 60.11 |
Long-Term Investments | 1.47 | 2.01 | 5.02 | 27.19 | 3.22 | 3.49 |
Long-Term Deferred Charges | - | - | - | - | - | 1.72 |
Other Long-Term Assets | 0.22 | - | 0.8 | 1.04 | 0.72 | - |
Total Assets | 81.68 | 61.95 | 92.09 | 138.74 | 102.56 | 65.32 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.97 | 3.02 | 3.32 | 2.68 | 2.12 | 1.06 |
Accrued Expenses | 2.84 | 4.47 | 6.13 | 10.7 | 5.01 | 2 |
Current Portion of Leases | - | - | - | - | 0.05 | - |
Other Current Liabilities | 0.78 | 1.23 | 0.79 | 0.67 | 0.01 | 0.33 |
Total Current Liabilities | 5.59 | 8.72 | 10.24 | 14.04 | 7.19 | 3.4 |
Other Long-Term Liabilities | 0.17 | 0.17 | - | - | 0 | 0.01 |
Total Liabilities | 5.76 | 8.89 | 10.24 | 14.04 | 7.19 | 3.41 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 335.11 | 293.95 | 287.59 | 278.88 | 185.47 | - |
Retained Earnings | -259.16 | -240.95 | -205.78 | -154.46 | -89.72 | -47.38 |
Comprehensive Income & Other | -0.02 | 0.06 | 0.03 | 0.28 | -0.37 | -0.03 |
Total Common Equity | 75.92 | 53.06 | 81.85 | 124.7 | 95.37 | -47.41 |
Shareholders' Equity | 75.92 | 53.06 | 81.85 | 124.7 | 95.37 | 61.91 |
Total Liabilities & Equity | 81.68 | 61.95 | 92.09 | 138.74 | 102.56 | 65.32 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | 0.05 | - |
Net Cash (Debt) | 78.39 | 58 | 83.62 | 107.3 | 96.01 | 58.56 |
Net Cash Growth | 24.59% | -30.64% | -22.07% | 11.76% | 63.96% | 1338.70% |
Net Cash Per Share | 2.25 | 1.92 | 2.80 | 4.55 | 6.26 | 22.20 |
Filing Date Shares Outstanding | 37.74 | 35.94 | 30.1 | 29.77 | 19.4 | 2.73 |
Total Common Shares Outstanding | 36.31 | 27.41 | 29.92 | 29.74 | 19.4 | 2.73 |
Working Capital | 74.41 | 51.22 | 76.02 | 96.46 | 91.44 | 56.71 |
Book Value Per Share | 2.09 | 1.94 | 2.74 | 4.19 | 4.92 | -17.36 |
Tangible Book Value | 75.92 | 53.06 | 81.85 | 124.7 | 95.37 | -47.41 |
Tangible Book Value Per Share | 2.09 | 1.94 | 2.74 | 4.19 | 4.92 | -17.36 |